P20 - The use of regulatory hexapeptide on frequently ill children by Maleyka Karimova
POSTER PRESENTATION Open Access
P20 - The use of regulatory hexapeptide on
frequently ill children
Maleyka Karimova
From 3rd Pediatric Allergy and Asthma Meeting (PAAM)
Athens, Greece. 17-19 October 2013
The use of regulatory hexapeptide at frequently ill children
Background. Respiratory diseases is one of the actual
problems of modern pediatrics. The aim is to study
clinical and laboratory level performance imunofan (
regulatory hexapepdide- alpha-arginyl-lysyl-aspartyl-valyl-
tyrosyl-arginine) at frequently ill children (FIC). Material
and methods.To this end, 42 children were examined
frequently ill with acute respiratory disease. The levels
of cytokines IL-1beta, IL-2, IL-6, IL-8, TNF-alpha,
IFN-gamma, serum level of substance P, condition
hemostasis ,of CD3, CD4, CD8, CD19 cell, content immu-
noglobulins A, M, G, E. It was also studied the intestinal
flora, microbiocenosis nasopharynx. Results.It was found
that in the acute period FIC marked increase in levels of
IL-1beta, IL-6,IL-8, TNF-alpha and substance P, blood
hypercoagulation, reduced IL-2 and IFN -gamma. Clinical
remission was not accompanied by normalization of
indicators. The high level of pro-inflammatory cytokines,
substance P and IgM, a tendency to hypercoagulability in
the period of clinical remission in FIC, reflects ongoing
inflammatory process, which in our opinion, due to the
persistence of the infectious agent. A significant reduction
in IL-2, IFN-gamma these children, due to the presence of
secondary immunodeficiency cell type. This is evidenced
by the reduced number of cellular immunity (CD3, CD4,
and the index of CD4 / CD8). In conclusion. Application
regulatory hexapepdide- imunofan at FIC leads to positive
dynamics of immunological parameters, sanitizes lasting
infections, eliminates bacteria overgrowth, prevent
complications and relapses. Imunofan has established itself
as a drug having anti-inflammatory activity in the
treatment of respiratory opportunistic infections.
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